Drug Recommendations, Legal Updates, Awards, Stock Price Movements, and Upcoming Results and Conference Call Schedules - Analyst Notes on MannKind, Mylan, WellPoint, Valeant, and Forest Laboratories

NEW YORK, April 7, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding MannKind Corporation (NASDAQ: MNKD), Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Valeant Pharmaceuticals International Inc. (NYSE: VRX), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

MannKind Corporation Analyst Notes 

On April 1, 2014, MannKind Corporation (MannKind) announced that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee has voted 13 to 1 to recommend that AFREZZA® (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type I diabetes. The same committee voted unanimously recommending that AFREZZA be granted marketing approval by the FDA to improve glycemic control in adults with type II diabetes. The Company informed that if AFREZZA is approved, then it would be the first ultra rapid-acting mealtime insulin therapy available in the U.S. On April 2, 2014, the Company's stock skyrocketed 73.88% to end the trading session at $6.99 following the news of recommendation of AFREZZA. The full analyst notes on MannKind Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04072014/MNKD/report.pdf

--

Mylan Inc. Analyst Notes 

On March 31, 2014, Mylan Inc. (Mylan) issued a press release informing that the U.S. Supreme Court has granted certiorari in the Company's patent litigation against Teva pertaining to Mylan's Abbreviated New Drug Application (ANDA) for glatiramer acetate (Copaxone). According to the press release, in July 2013, the Court of Appeals for the Federal Circuit ruled a decision that Teva's U.S. Patent No. 5,800,808 (the '808 patent), along with other patents, was invalid as indefinite. As stated, the Supreme Court is also considering the issue of the standard of review that appellate courts should apply when considering appeals relating to the construction of a patent claim. The Supreme Court has also agreed to consider a query of Teva that whether a legal review of district court's factual finding in support of its construction of a patent claim should be carried out, as the Federal Circuit looks for clear factual errors. The full analyst notes on Mylan Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/MYL/report.pdf

--

WellPoint Inc. Analyst Notes 

On April 1, 2014, WellPoint Inc. (WellPoint) announced that it has been awarded with the Corporate Hispanic Health Leadership Award from the National Hispanic Medical Association (NHMA) recognizing its efforts in educating the Hispanic community on the Affordable Care Act. According to the Company, NHMA has acknowledged the Company's efforts in helping to enroll uninsured Hispanics in their communities. Dr. Antonio Linares, Regional Vice President and Medical Director at WellPoint, said, "It is WellPoint's goal to make sure that Hispanic American families in the communities we serve can control their own health care journey by taking advantage of their many new insurance options, including plans available through the new exchanges." The full analyst notes on WellPoint Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/WLP/report.pdf

--

Valeant Pharmaceuticals International Inc. Analyst Notes 

On April 2, 2014, shares of Valeant Pharmaceuticals International Inc. (Valeant) moved up 0.33% to end the trading session at $133.69, extending gains for the fourth consecutive session. Valeant's stock opened the trading session at $134.34 and fluctuated in the range of $131.82 and $135.83. The stock has a 52-week high of $153.10 and a 52-week low of $69.87. Over the past three months, the stock has gained 14.27%, outperforming the S&P 500 Index which gained 3.22% over the same period. The full analyst notes on Valeant Pharmaceuticals International Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/VRX/report.pdf

--

Forest Laboratories Inc. Analyst Notes 

On April 1, 2014, Forest Laboratories Inc. (Forest Laboratories) announced that the Company plans to release its Q4 FY 2014 results on April 29, 2014, before the opening of the U.S. stock market. Following the earnings release, the Company will also hold a conference call at 10:00 a.m. EDT to discuss the financial results and relevant company and industry issues. According to Zacks Investment Research data, the consensus EPS forecast for Q4 FY 2014 is $0.44. The full analyst notes on Forest Laboratories Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/FRX/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review